Bavda Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-06-2024
- Paid Up Capital ₹ 0.71 M
as on 23-06-2024
- Company Age 35 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 23-06-2024
- Satisfied Charges ₹ 1.50 Cr
as on 23-06-2024
- Revenue -1.77%
(FY 2018)
- Profit 15.77%
(FY 2018)
- Ebitda -13.31%
(FY 2018)
- Net Worth 4.70%
(FY 2018)
- Total Assets 9.45%
(FY 2018)
About Bavda Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.71 M.
The company currently has active open charges totaling ₹4.00 M. The company has closed loans amounting to ₹1.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bal Agarwal and Neelu Agarwal serve as directors at the Company.
- CIN/LLPIN
U31909WB1989PTC046165
- Company No.
046165
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Feb 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bavda Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bal Agarwal  | Director | 08-Feb-1989 | Current |
| Neelu Agarwal | Director | 14-Mar-2007 | Current |
Financial Performance of Bavda Pharmaceuticals.
Bavda Pharmaceuticals Private Limited, for the financial year ended 2018, experienced Minor drop in revenue, with a 1.77% decrease. The company also saw a substantial improvement in profitability, with a 15.77% increase in profit. The company's net worth moved up by a moderate rise of 4.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bavda Pharmaceuticals?
In 2019, Bavda Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Bavda Pharma Private LimitedActive 3 years 10 months
Bal Agarwal and Neelu Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 16 Oct 2023 | ₹4.00 M | Open |
Yes Bank Limited Creation Date: 14 Feb 2014 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Bavda Pharmaceuticals?
Unlock and access historical data on people associated with Bavda Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bavda Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bavda Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
